Incyte (INCY) Competitors $85.04 -1.49 (-1.72%) Closing price 04:00 PM EasternExtended Trading$85.15 +0.11 (+0.13%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INCY vs. ABBV, REGN, ALNY, BIIB, UTHR, NBIX, BMRN, EXEL, EXAS, and HALOShould you be buying Incyte stock or one of its competitors? The main competitors of Incyte include AbbVie (ABBV), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Exact Sciences (EXAS), and Halozyme Therapeutics (HALO). These companies are all part of the "medical" sector. Incyte vs. Its Competitors AbbVie Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences BioMarin Pharmaceutical Exelixis Exact Sciences Halozyme Therapeutics Incyte (NASDAQ:INCY) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability. Do analysts prefer INCY or ABBV? Incyte presently has a consensus target price of $81.60, suggesting a potential downside of 4.05%. AbbVie has a consensus target price of $214.95, suggesting a potential upside of 2.22%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Incyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incyte 1 Sell rating(s) 10 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.33AbbVie 0 Sell rating(s) 6 Hold rating(s) 16 Buy rating(s) 5 Strong Buy rating(s) 2.96 Which has higher valuation & earnings, INCY or ABBV? AbbVie has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIncyte$4.24B3.92$32.62M$4.4019.33AbbVie$58.33B6.37$4.28B$2.10100.14 Does the media refer more to INCY or ABBV? In the previous week, AbbVie had 66 more articles in the media than Incyte. MarketBeat recorded 99 mentions for AbbVie and 33 mentions for Incyte. AbbVie's average media sentiment score of 1.03 beat Incyte's score of 0.84 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 15 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive AbbVie 65 Very Positive mention(s) 8 Positive mention(s) 17 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Positive Is INCY or ABBV more profitable? Incyte has a net margin of 18.99% compared to AbbVie's net margin of 6.45%. AbbVie's return on equity of 699.66% beat Incyte's return on equity.Company Net Margins Return on Equity Return on Assets Incyte18.99% 21.99% 14.43% AbbVie 6.45%699.66%13.64% Which has more volatility & risk, INCY or ABBV? Incyte has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Do institutionals & insiders have more ownership in INCY or ABBV? 97.0% of Incyte shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 17.8% of Incyte shares are owned by insiders. Comparatively, 0.3% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryAbbVie beats Incyte on 11 of the 17 factors compared between the two stocks. Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCY vs. The Competition Export to ExcelMetricIncyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.61B$3.09B$5.82B$9.73BDividend YieldN/A2.23%3.84%4.09%P/E Ratio19.3321.1431.1525.96Price / Sales3.92398.37475.15122.97Price / Cash155.7143.0937.1558.38Price / Book3.988.079.116.39Net Income$32.62M-$54.72M$3.26B$265.56M7 Day Performance-2.16%2.62%2.11%1.98%1 Month Performance23.43%7.63%5.12%1.33%1 Year Performance34.94%13.11%31.25%21.15% Incyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCYIncyte4.7354 of 5 stars$85.04-1.7%$81.60-4.0%+34.9%$16.61B$4.24B19.332,617Trending NewsAnalyst ForecastABBVAbbVie4.7647 of 5 stars$198.46+0.2%$214.43+8.0%+6.6%$349.87B$56.33B94.5055,000Trending NewsREGNRegeneron Pharmaceuticals4.8577 of 5 stars$545.94-3.0%$826.91+51.5%-49.5%$59.67B$14.20B13.7615,106Positive NewsDividend AnnouncementALNYAlnylam Pharmaceuticals4.1912 of 5 stars$435.00-0.9%$403.92-7.1%+67.5%$57.53B$2.25B-176.112,230Insider TradeBIIBBiogen4.8527 of 5 stars$128.00-2.0%$185.63+45.0%-32.5%$19.16B$9.68B12.247,605Positive NewsUTHRUnited Therapeutics4.9113 of 5 stars$300.43-0.4%$379.69+26.4%-11.6%$13.60B$2.88B11.731,305Positive NewsInsider TradeNBIXNeurocrine Biosciences4.8699 of 5 stars$123.98-0.8%$160.90+29.8%-10.3%$12.40B$2.36B36.681,800Positive NewsBMRNBioMarin Pharmaceutical4.9979 of 5 stars$56.80-0.9%$93.17+64.0%-37.3%$11.01B$2.85B16.853,040EXELExelixis4.9113 of 5 stars$37.41-0.8%$44.44+18.8%+47.0%$10.15B$2.17B17.991,147Trending NewsAnalyst RevisionEXASExact Sciences4.9099 of 5 stars$40.91-0.2%$68.14+66.6%-21.8%$7.76B$2.76B-7.537,000HALOHalozyme Therapeutics4.7103 of 5 stars$62.92+0.0%$66.56+5.8%+15.2%$7.75B$1.02B14.40390News CoveragePositive News Related Companies and Tools Related Companies AbbVie Competitors Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Neurocrine Biosciences Competitors BioMarin Pharmaceutical Competitors Exelixis Competitors Exact Sciences Competitors Halozyme Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INCY) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access